FDA gains power to police compounding pharmacies copying commercial drugs
H.R. 6509 — SAFE Drugs Act of 2025 · Filed by Rudy Yakym (R-IN) · 19 cosponsors · Introduced Dec 9, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill tightens federal oversight of compounding pharmacies and outsourcing facilities by restricting them from repeatedly copying commercially available drugs, requiring them to report when they compound copies of commercial drugs for out-of-state patients, and mandating more frequent inspections of large-scale outsourcing facilities. The bill aims to prevent compounding pharmacies from functioning as unlicensed drug manufacturers while preserving their legitimate role in customizing medications for individual patients.
Why we flagged it
The bill's operative mechanism is regulatory tightening: it restricts compounding pharmacies from copying commercial drugs at scale, requires reporting of out-of-state compounding, and mandates biennial inspections of large-scale facilities. These are safety and oversight measures, not market protection.
What the text implies
- The 20-times-per-month threshold for 'essentially a copy' compounding may be difficult for regulators to enforce without detailed pharmacy records; compliance burden falls on smaller compounders who lack IT infrastructure.
- The definition of 'essentially a copy' depends on prescriber judgment of 'significant difference' — this creates ambiguity and potential for regulatory disputes over subjective clinical determinations.
The full analysis lists 5 implications of this text.
Who stands to gain
Pharmaceutical manufacturers (reduced competition from compounded copies); FDA and HHS (increased inspection and enforcement budget authority)